Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study by Gupta, V, Kosiorek, H, Mead, A, Klisovic, R, Galvin, J, Berenzon, D, Yacoub, A, Viswabandya, A, Mesa, R, Goldberg, J, Price, L, Salama, M, Weinberg, R, Rampal, R, Farnoud, N, Dueck, A, Mascarenhas, J, Hoffman, R